Main indications for Rucaparib

Rucaparib (Rucaparib) is an oral multi-target PARP (poly ADP ribose polymerase) inhibitor, mainly used for tumor treatment targeting specific genetic backgrounds. Its main indications include ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The therapeutic effect of this type of drug is usually closely related to the BRCA gene mutation status in the patient's body. Therefore, before use, doctors will recommend that patients undergo BRCA gene testing to determine whether they belong to a group of patients suitable for treatment with rucapanib. BRCA gene abnormalities can lead to a decrease in DNA damage repair ability, and PARP inhibitors increase the lethality of cancer cells by blocking the repair pathway, thus exerting targeted therapeutic effects. This makes rucapanib highly targeted in cancer treatment. For patients carrying BRCA mutations, the drug can not only delay disease progression, but also improve quality of life to a certain extent.

In addition to gynecological tumors, rucapanib is also approved for the treatment of prostate cancer patients with BRCA gene abnormalities, especially those whose cancer has spread to other parts of the body and surgery or conventional treatments cannot achieve satisfactory results. In these settings, rucaparib offers a new option as a targeted therapy, especially for individuals who have responded poorly to standard chemotherapy or are at risk for resistance. Clinical studies have shown that PARP inhibitors are highly effective in patients with BRCA mutations, so rucapanib is regarded as an important component of precision medicine. In actual use, doctors will formulate an individualized medication plan based on the patient's disease stage, genetic background, and previous treatment history to ensure that the drug maximizes its efficacy and reduces potential adverse reactions.

The treatment concept of rucapanib embodies the application of precision medicine in the field of cancer, achieving more effective treatment by targeting genetic defects while avoiding excessive damage to healthy tissue. This treatment method not only improves patients' treatment tolerance, but also provides new treatment ideas for patients with advanced or refractory cancer.

Reference materials:https://www.drugs.com/mtm/rucaparib.html